InCarda Therapeutics Status
The company raised $42 million of Series B venture funding in a deal led by HealthCap and Sofinnova Ventures on November 8, 2018. Asset Management Ventures, Deerfield Management and Morningside Venture Capital also participated in the round. Proceeds from the financing will be used primarily to fund the recently initiated Phase 2 study of InRhythm (flecainide for inhalation), the company's lead development program, for the treatment of recent-onset paroxysmal atrial fibrillation (PAF).
Add a review